EVOLENT HEALTH INC - A (EVH)
US30050B1017 - Common Stock
Overall EVH gets a fundamental rating of 4 out of 10. We evaluated EVH against 40 industry peers in the Health Care Technology industry. The financial health of EVH is average, but there are quite some concerns on its profitability. EVH has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
EVH had positive earnings in the past year.
In the past year EVH had a positive cash flow from operations.
EVH had negative earnings in each of the past 5 years.
In multiple years EVH reported negative operating cash flow during the last 5 years.
1.2 Ratios
EVH has a better Return On Assets (-5.31%) than 74.36% of its industry peers.
EVH's Return On Equity of -11.42% is fine compared to the rest of the industry. EVH outperforms 74.36% of its industry peers.
EVH has a Return On Invested Capital of 1.41%. This is amongst the best in the industry. EVH outperforms 87.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.31% | ||
| ROE | -11.42% | ||
| ROIC | 1.41% |
ROA(3y)-3%
ROA(5y)-10.71%
ROE(3y)-6.36%
ROE(5y)-21.15%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EVH has a Operating Margin of 1.83%. This is amongst the best in the industry. EVH outperforms 87.18% of its industry peers.
EVH has a worse Gross Margin (23.45%) than 87.18% of its industry peers.
In the last couple of years the Gross Margin of EVH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.83% | ||
| PM (TTM) | N/A | ||
| GM | 23.45% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.68%
GM growth 5Y-13.25%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so EVH is destroying value.
Compared to 1 year ago, EVH has more shares outstanding
The number of shares outstanding for EVH has been increased compared to 5 years ago.
The debt/assets ratio for EVH has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 1.84 indicates that EVH is not a great score, but indicates only limited risk for bankruptcy at the moment.
EVH has a Altman-Z score of 1.84. This is in the better half of the industry: EVH outperforms 74.36% of its industry peers.
The Debt to FCF ratio of EVH is 5.24, which is a neutral value as it means it would take EVH, 5.24 years of fcf income to pay off all of its debts.
EVH's Debt to FCF ratio of 5.24 is fine compared to the rest of the industry. EVH outperforms 79.49% of its industry peers.
A Debt/Equity ratio of 0.48 indicates that EVH is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.48, EVH is not doing good in the industry: 64.10% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 5.24 | ||
| Altman-Z | 1.84 |
ROIC/WACC0.13
WACC10.68%
2.3 Liquidity
A Current Ratio of 1.01 indicates that EVH should not have too much problems paying its short term obligations.
EVH has a Current ratio of 1.01. This is in the lower half of the industry: EVH underperforms 69.23% of its industry peers.
A Quick Ratio of 1.01 indicates that EVH should not have too much problems paying its short term obligations.
EVH's Quick ratio of 1.01 is on the low side compared to the rest of the industry. EVH is outperformed by 69.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.01 | ||
| Quick Ratio | 1.01 |
3. Growth
3.1 Past
EVH shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.30%.
Looking at the last year, EVH shows a very strong growth in Revenue. The Revenue has grown by 45.26%.
EVH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 25.65% yearly.
EPS 1Y (TTM)-3.3%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q130%
Revenue 1Y (TTM)45.26%
Revenue growth 3Y28.54%
Revenue growth 5Y25.65%
Revenue growth Q2Q45.41%
3.2 Future
The Earnings Per Share is expected to grow by 29.10% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 12.95% on average over the next years. This is quite good.
EPS Next Y32.96%
EPS Next 2Y36.74%
EPS Next 3Y28.71%
EPS Next 5Y29.1%
Revenue Next Year26.55%
Revenue Next 2Y21.06%
Revenue Next 3Y18.82%
Revenue Next 5Y12.95%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 33.66 indicates a quite expensive valuation of EVH.
Compared to the rest of the industry, the Price/Earnings ratio of EVH indicates a rather cheap valuation: EVH is cheaper than 89.74% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of EVH to the average of the S&P500 Index (24.80), we can say EVH is valued slightly more expensively.
Based on the Price/Forward Earnings ratio of 25.31, the valuation of EVH can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EVH indicates a rather cheap valuation: EVH is cheaper than 89.74% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.27. EVH is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.66 | ||
| Fwd PE | 25.31 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, EVH is valued a bit cheaper than 79.49% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, EVH is valued a bit cheaper than the industry average as 79.49% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 30.03 | ||
| EV/EBITDA | 24.01 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as EVH's earnings are expected to grow with 28.71% in the coming years.
PEG (NY)1.02
PEG (5Y)N/A
EPS Next 2Y36.74%
EPS Next 3Y28.71%
5. Dividend
5.1 Amount
EVH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EVOLENT HEALTH INC - A
NYSE:EVH (4/18/2024, 7:04:00 PM)
After market: 29.62 0 (0%)29.62
-0.02 (-0.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.42B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.66 | ||
| Fwd PE | 25.31 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)1.02
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.31% | ||
| ROE | -11.42% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 1.83% | ||
| PM (TTM) | N/A | ||
| GM | 23.45% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.01 | ||
| Quick Ratio | 1.01 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-3.3%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y32.96%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)45.26%
Revenue growth 3Y28.54%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y